feed,title,long_url,short_url
Benzinga,Celebree School Selected a Top Emerging Franchise for 2021 by Franchise Gator,https://www.benzinga.com/pressreleases/21/02/g19645082/celebree-school-selected-a-top-emerging-franchise-for-2021-by-franchise-gator,https://j.mp/2Op7u2m
Benzinga,Why Consumers Are Buying More Lawn & Garden Equipment amid the COVID-19 Pandemic,https://www.benzinga.com/pressreleases/21/02/n19645095/why-consumers-are-buying-more-lawn-garden-equipment-amid-the-covid-19-pandemic,https://j.mp/3aYLYt8
Benzinga,Astellas and Seagen Announce Presentation of Results from PADCEV速 (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy,https://www.benzinga.com/pressreleases/21/02/n19645019/astellas-and-seagen-announce-presentation-of-results-from-padcev-enfortumab-vedotin-ejfv-pivotal-t,https://j.mp/377tc1o
Benzinga,Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV速 (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer,https://www.benzinga.com/pressreleases/21/02/n19645018/astellas-and-seagen-announce-phase-3-trial-results-demonstrating-survival-advantage-of-padcev-enfo,https://j.mp/3jHzaLF
Benzinga,Global Power Generation Market Outlook to 2024 - Rapid Industrialization and Favorable Government Policies and Initiatives are Driving Growth,https://www.benzinga.com/pressreleases/21/02/n19645017/global-power-generation-market-outlook-to-2024-rapid-industrialization-and-favorable-government-po,https://j.mp/3jR7aW0
Benzinga,Seagen and Astellas Announce Presentation of Results from PADCEV速 (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy,https://www.benzinga.com/pressreleases/21/02/b19645015/seagen-and-astellas-announce-presentation-of-results-from-padcev-enfortumab-vedotin-ejfv-pivotal-t,https://j.mp/3phdV4g
Benzinga,Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV速 (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer,https://www.benzinga.com/pressreleases/21/02/b19645014/seagen-and-astellas-announce-phase-3-trial-results-demonstrating-survival-advantage-of-padcev-enfo,https://j.mp/3aeLcJ4
